Literature DB >> 362926

Pituitary tumors and pregnancy.

D M Magyar, J R Marshall.   

Abstract

This paper contains a review of the natural history of pituitary tumors in nonpregnant and pregnant patients. Data were drawn from previously published reports and from responses to a questionnaire and were analyzed by life-table techniques. Follow-up of 62 nonpregnant patients with untreated pituitary tumors with and without visual field changes revealed a median time to treatment of 15 1/2 years and similar, relatively constant hazard functions. In 91 pregnancies occurring in 73 women with previously untreated pituitary tumors, ovulation had occurred spontaneously in 9 per cent, headache occurred in 23 per cent, and visual disturbances in 25 per cent with 61 per cent remaining asymptomatic. In those patients who developed symptoms, median time to headache was 10 weeks and to visual disturbance, 14 weeks. The hazard functions were relatively constant and similar. The relative risk of developing symptoms is independent of whether or not the first or second pregnancy occurred in the presence of the pituitary tumor. Of the pregnant patients with previously untreated pituitary tumors, 30 per cent required surgery or radiation therapy. Median time to treatment was 19 weeks. None of the 69 pregnant women without pituitary therapy had permanent sequelae. Only four patients who underwent surgery or received radiation treatment developed permanent symptoms and none was serious. In 78 pregnancies occurring in 73 women with previously treated pituitary tumors, headache occurred in 4 per cent and visual disturbances in 5 per cent. Only one patient required therapy. Treatment during pregnancy results in significantly increased prematurity rates but unchanged abortion and perinatal mortality rates. Small pituitary tumors do not constitute a contraindication to either induction of ovulation or pregnancy.

Entities:  

Mesh:

Year:  1978        PMID: 362926     DOI: 10.1016/s0002-9378(78)80008-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  23 in total

Review 1.  Medical management of pituitary adenomas: the special case of management of the pregnant woman.

Authors:  Marcello Delano Bronstein; Luiz Roberto Salgado; Nina Rosa de Castro Musolino
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Ophthalmic considerations in pregnancy.

Authors:  Sushil Chawla; Tarun Chaudhary; S Aggarwal; G D Maiti; Kulharsh Jaiswal; Jairam Yadav
Journal:  Med J Armed Forces India       Date:  2013-06-06

Review 3.  Management of endocrine disorders in pregnancy. Part II. Pituitary, ovarian and adrenal disease.

Authors:  Z M van der Spuy; H S Jacobs
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

Review 4.  Pituitary microadenomas: diagnostic and therapeutic trends.

Authors:  E M Grimes
Journal:  J Natl Med Assoc       Date:  1984-10       Impact factor: 1.798

5.  Treatment of prolactinomas with megavoltage radiotherapy.

Authors:  A Grossman; B L Cohen; M Charlesworth; P N Plowman; L H Rees; J A Wass; A E Jones; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

6.  Acromegaly in pregnancy.

Authors:  T George Koshy; Simon Rajaratnam; Jiji Elizabeth Mathews; Vedantam Rajshekhar
Journal:  Indian J Endocrinol Metab       Date:  2012-11

Review 7.  Bromocriptine in the treatment of hypogonadism and male impotence.

Authors:  C M March
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

8.  Spontaneous regression of pituitary mass in temporal association with pregnancy.

Authors:  H Ikeda; Y Okudaira
Journal:  Neuroradiology       Date:  1987       Impact factor: 2.804

9.  Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy.

Authors:  T Bergh; S J Nillius; P Enoksson; L Wide
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

Review 10.  Diagnosis and management of prolactinomas.

Authors:  J R Dollar; R E Blackwell
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.